Nkarta IncNASDAQ NKTX Stock Report

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 163 full-time employees. The company went IPO on 2020-07-10. The company has two co-lead products, NKX101 and NKX019, in ongoing Phase I clinical trials. Its platform incorporates technologies that enable to generate supply of NK cells and enhance cell fitness and tumor microenvironment evasion, freeze, store and thaw its engineered NK cells for off-the-shelf use for the treatment of cancer. Its product candidates and discovery programs NKX101 is designed to innate NK biology to detect and kill cancerous cells. Its primary activating receptor NKG2D, works through the detection of stress ligands displayed by cancerous cells. The company has engineered NKX101 to increase the cancer cell killing ability of its engineered NK cells by raising levels of NKG2D. Its NKX019 treats a variety of B-cell malignancies by targeting the CD19 antigen that is found on these types of cancerous cells.